Unfortunately, it has been difficult to separate the effects of baseline IFNα/β activity and the use of immunosuppressive therapies, which result in an increased incidence of multiple viral infections in patients with SLE (48). The gene discussed is IFNA2; the disease is systemic lupus erythematosus.